PH12021553231A1 - Hepatitis b core protein allosteric modulators - Google Patents

Hepatitis b core protein allosteric modulators

Info

Publication number
PH12021553231A1
PH12021553231A1 PH1/2021/553231A PH12021553231A PH12021553231A1 PH 12021553231 A1 PH12021553231 A1 PH 12021553231A1 PH 12021553231 A PH12021553231 A PH 12021553231A PH 12021553231 A1 PH12021553231 A1 PH 12021553231A1
Authority
PH
Philippines
Prior art keywords
hepatitis
core protein
allosteric modulators
protein allosteric
virus
Prior art date
Application number
PH1/2021/553231A
Other languages
English (en)
Inventor
Lee Daniel Arnold
Hans Maag
William W Turner
Adam Zlotnick
Original Assignee
Assembly Biosciences Inc
Univ Indiana Res & Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assembly Biosciences Inc, Univ Indiana Res & Tech Corp filed Critical Assembly Biosciences Inc
Publication of PH12021553231A1 publication Critical patent/PH12021553231A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C07D223/20—Dibenz [b, e] azepines; Hydrogenated dibenz [b, e] azepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/38—[b, e]- or [b, f]-condensed with six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D281/14—[b, e]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D281/16—[b, f]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PH1/2021/553231A 2014-03-13 2015-03-13 Hepatitis b core protein allosteric modulators PH12021553231A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461952467P 2014-03-13 2014-03-13
US201462010025P 2014-06-10 2014-06-10
PCT/US2015/020444 WO2015138895A1 (en) 2014-03-13 2015-03-13 Hepatitis b core protein allosteric modulators

Publications (1)

Publication Number Publication Date
PH12021553231A1 true PH12021553231A1 (en) 2023-01-23

Family

ID=54072461

Family Applications (2)

Application Number Title Priority Date Filing Date
PH1/2021/553231A PH12021553231A1 (en) 2014-03-13 2015-03-13 Hepatitis b core protein allosteric modulators
PH1/2016/501762A PH12016501762B1 (en) 2014-03-13 2015-03-13 Hepatitis b core protein allosteric modulators

Family Applications After (1)

Application Number Title Priority Date Filing Date
PH1/2016/501762A PH12016501762B1 (en) 2014-03-13 2015-03-13 Hepatitis b core protein allosteric modulators

Country Status (23)

Country Link
US (3) US10183936B2 (2)
EP (3) EP3116316B1 (2)
JP (2) JP6602311B2 (2)
KR (1) KR102363174B1 (2)
CN (2) CN106413402B (2)
AP (1) AP2016009477A0 (2)
AU (2) AU2015229174B2 (2)
CA (1) CA2942533C (2)
CL (1) CL2016002269A1 (2)
DK (1) DK3116316T3 (2)
DO (1) DOP2016000233A (2)
ES (1) ES2748029T3 (2)
HR (1) HRP20191444T1 (2)
HU (1) HUE046567T2 (2)
IL (3) IL247575B (2)
MX (2) MX363600B (2)
PH (2) PH12021553231A1 (2)
PL (1) PL3116316T3 (2)
PT (1) PT3116316T (2)
RS (1) RS59430B1 (2)
SG (2) SG10202001506UA (2)
WO (1) WO2015138895A1 (2)
ZA (1) ZA201606209B (2)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014015197A8 (pt) 2011-12-21 2017-06-13 Novira Therapeutics Inc agentes antivirais de hepatite b
KR102271574B1 (ko) 2012-08-28 2021-07-01 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 설파모일-아릴아미드 및 b형 간염 치료제로서의 그 용도
WO2014131847A1 (en) 2013-02-28 2014-09-04 Janssen R&D Ireland Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
MX353412B (es) 2013-04-03 2018-01-10 Janssen Sciences Ireland Uc Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
TWI733288B (zh) 2013-05-17 2021-07-11 愛爾蘭商健生科學愛爾蘭無限公司 胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途
DK2997019T3 (en) 2013-05-17 2018-12-03 Janssen Sciences Ireland Uc SULFAMOYLTHIOPHENAMIDE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATING HEPATITIS B
HRP20180791T1 (hr) 2013-07-25 2018-09-07 Janssen Sciences Ireland Uc Glioksamid supstituirani derivati pirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b
CA2923712C (en) 2013-10-23 2021-11-02 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
CA2936947A1 (en) 2014-02-05 2015-08-13 Novira Therapeutics, Inc. Combination therapy for treatment of hbv infections
TW201620893A (zh) 2014-02-06 2016-06-16 健生科學愛爾蘭無限公司 磺醯胺基吡咯醯胺衍生物及其用作治療ｂ型肝炎之醫藥品的用途
ES2748029T3 (es) 2014-03-13 2020-03-12 Univ Indiana Res & Tech Corp Moduladores alostéricos de proteína núcleo de hepatitis B
JP2018510159A (ja) 2015-03-19 2018-04-12 ノヴィラ・セラピューティクス・インコーポレイテッド アゾカン及びアゾナン誘導体及びｂ型肝炎感染症の治療法
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
CN108025034B (zh) * 2015-07-15 2022-09-30 新加坡科技研究局 乙型肝炎病毒复制的调控
TWI721016B (zh) * 2015-09-15 2021-03-11 美商艾森伯利生物科學公司 B型肝炎核心蛋白質調節劑
TW201718496A (zh) 2015-09-29 2017-06-01 諾維拉治療公司 B型肝炎抗病毒劑之晶型
AU2017248828A1 (en) 2016-04-15 2018-11-01 Janssen Sciences Ireland Uc Combinations and methods comprising a capsid assembly inhibitor
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
ES2990061T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros espirocíclicos para la degradación de proteínas diana
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
EP3454856B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
AU2017326356A1 (en) 2016-09-15 2019-04-11 Assembly Biosciences, Inc. Hepatitis B core protein modulators
KR20190092374A (ko) 2016-10-03 2019-08-07 시질론 테라퓨틱스, 인크. 화합물, 장치, 및 이의 용도
SG11201902944TA (en) 2016-11-07 2019-05-30 Arbutus Biopharma Corp Substituted pyridinone-containing tricyclic compounds, and methods using same
CN106632177A (zh) * 2016-12-05 2017-05-10 万特制药(海南)有限公司 雷美替胺中间体的制备方法
US11053260B2 (en) * 2017-02-23 2021-07-06 Fujian Cosunter Pharmaceutical Co., Ltd. Tri-cycle compound and applications thereof
CA3055194A1 (en) 2017-03-02 2018-09-07 Assembly Biosciences, Inc. Cyclic sulfamide compounds and methods of using same
AU2018236188B2 (en) * 2017-03-13 2022-01-27 Assembly Biosciences, Inc. Process for making hepatitis B core protein modulators
MA49014A (fr) 2017-03-21 2020-02-05 Arbutus Biopharma Corp Dihydroindène-4-carboxamides substitués, leurs analogues et procédés d'utilisation correspondant
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
ES2946917T3 (es) 2017-07-21 2023-07-27 Antabio Sas Compuestos químicos
EA202091113A1 (ru) 2017-11-02 2020-08-28 Айкурис Гмбх Унд Ко. Кг Новые высокоактивные аминотиазолзамещенные индол-2-карбоксамиды, активные в отношении вируса гепатита b (hbv)
KR20200083552A (ko) 2017-11-02 2020-07-08 아이쿠리스 게엠베하 운트 코. 카게 B형 간염 바이러스 (hbv)에 활성인 신규 고활성 피라졸로-피페리딘 치환된 인돌-2-카르복스아미드
MX2020009531A (es) 2018-03-14 2020-10-05 Janssen Sciences Ireland Unlimited Co Regimen posologico del modulador del ensamblaje de la capside.
WO2019213584A1 (en) * 2018-05-03 2019-11-07 Emory University Modulators of orphan nuclear receptors for nash and other metabolic disorders
CN110627752B (zh) * 2018-06-25 2021-08-17 新发药业有限公司 一种3-氨甲基四氢呋喃的制备方法
CN108863884B (zh) * 2018-07-26 2020-07-03 南京富润凯德生物医药有限公司 一种用dast试剂作为消除试剂合成共轭硝基烯取代系列衍生物的方法
TWI826492B (zh) 2018-07-27 2023-12-21 加拿大商愛彼特生物製藥公司 經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法
CA3109746C (en) * 2018-08-23 2023-07-11 Fujian Cosunter Pharmaceutical Co., Ltd. Crystal form of tri-cycle compound and application thereof
AR117189A1 (es) 2018-11-02 2021-07-21 Aicuris Gmbh & Co Kg Derivados de 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activos contra el virus de la hepatitis b (vhb)
AR116946A1 (es) 2018-11-02 2021-06-30 Aicuris Gmbh & Co Kg Derivados de urea 6,7-dihidro-4h-pirazolo[4,3-c]piridinas activas contra el virus de la hepatitis b (vhb)
UY38437A (es) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg Nuevas urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (hbv)
PY1991611A (es) 2018-11-02 2022-03-14 Aicuris Gmbh & Co Kg Nueva urea 6,7-dihidro-4h-pirazolo [1,5-a] pirazinas activas contra el virus de la hepatitis b (vhb)
PY1991603A (es) 2018-11-02 2020-09-17 Aicuris Gmbh & Co Kg Nueva 6,7-dihidro-4h-pirazolo [1,5-a] pirazina indole -2-carboxamidas activas contra el virus de la hepatitis b (vhb)
TW202415643A (zh) 2018-12-12 2024-04-16 加拿大商愛彼特生物製藥公司 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
CN120698983A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
WO2020169784A1 (en) 2019-02-22 2020-08-27 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases
BR112021021564A2 (pt) 2019-04-30 2022-01-04 Aicuris Gmbh & Co Kg Indol-2-carboxamidas inovadoras ativas contra o vírus da hepatite b (hbv)
WO2020221824A1 (en) 2019-04-30 2020-11-05 Aicuris Gmbh & Co. Kg Novel indolizine-2-carboxamides active against the hepatitis b virus (hbv)
US20220227785A1 (en) 2019-04-30 2022-07-21 Aicuris Gmbh & Co. Kg Novel phenyl and pyridyl ureas active against the hepatitis b virus (hbv)
JP2022533008A (ja) 2019-04-30 2022-07-21 アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト Ｂ型肝炎ウイルス（ｈｂｖ）に対し活性な新規のオキサリルピペラジン
AR119732A1 (es) 2019-05-06 2022-01-05 Janssen Sciences Ireland Unlimited Co Derivados de amida útiles en el tratamiento de la infección por vhb o de enfermedades inducidas por vhb
BR112021023622A2 (pt) * 2019-05-24 2022-04-19 Assembly Biosciences Inc Composições farmaceuticas para o tratamento de hbv
CN110526878A (zh) * 2019-09-16 2019-12-03 成都睿智化学研究有限公司 一种2-(噁唑基)乙胺的制备方法
CN111072551A (zh) * 2019-12-30 2020-04-28 上海睿瓦科技有限公司 催化氢化一步法制取哌啶胺的方法
CN121248511A (zh) * 2020-04-22 2026-01-02 组装生物科学股份有限公司 用于治疗hbv的5元杂芳基甲酰胺化合物
CN113135848A (zh) * 2021-04-26 2021-07-20 深圳市华先医药科技有限公司 一种巯基烯酯类化合物的制备方法
CN113636960A (zh) * 2021-08-24 2021-11-12 上海皓元医药股份有限公司 一种2-(氯磺酰基)环己烷-1-烯甲酸乙酯衍生物的制备方法
CN113717080A (zh) * 2021-10-09 2021-11-30 西安瑞联新材料股份有限公司 一种4-氯-2-氰基苯磺酰氯的合成方法
CN115353479A (zh) * 2022-07-27 2022-11-18 常州琦诺生物科技有限公司 一种5-溴-2-碘嘧啶的制备方法
WO2024089216A1 (en) 2022-10-27 2024-05-02 Syngenta Crop Protection Ag Novel sulfur-containing heteroaryl carboxamide compounds
WO2025069039A1 (en) * 2023-09-28 2025-04-03 Rajaram Samant An in situ process for the preparation of primary amine compounds

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1480553A (en) * 1976-06-03 1977-07-20 Pfizer Ltd Tricyclic sulphonamides
JPS58225074A (ja) * 1982-06-25 1983-12-27 Chugai Pharmaceut Co Ltd ジベンゾオキサゼピン誘導体
GB9109557D0 (en) * 1991-05-02 1991-06-26 Wellcome Found Chemical compounds
US5512563A (en) 1993-07-29 1996-04-30 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US20070208166A1 (en) * 2003-10-24 2007-09-06 Exelixis, Inc. Tao Kinase Modulators And Method Of Use
DE102004004928A1 (de) * 2004-01-31 2005-08-18 Bayer Healthcare Ag Dibenzoxazepine II
WO2007047737A1 (en) 2005-10-17 2007-04-26 Acadia Pharmaceuticals Inc. Cb-1 modulating compounds and their use
WO2007056388A2 (en) 2005-11-07 2007-05-18 The General Hospital Corporation Compositions and methods for modulating poly (adp-ribose) polymerase activity
US20100022509A1 (en) 2006-06-07 2010-01-28 Fahey Robert C Inhibitors of MshC and Homologs Thereof, and Methods of Identifying Same
WO2008118141A2 (en) 2006-10-17 2008-10-02 Acadia Pharmaceuticals Inc. Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy
AU2009274255A1 (en) 2008-07-23 2010-01-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of the plasmodial surface anion channel as antimalarials
US20110152246A1 (en) * 2009-12-18 2011-06-23 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
WO2012045194A1 (en) 2010-10-09 2012-04-12 Abbott Laboratories Benzodiazepinones as fak inhibitors for treatment of cancer
JP5977347B2 (ja) 2011-07-01 2016-08-24 バルーク エス．ブルームバーグ インスティテュート Ｈｂｖ感染に対する抗ウイルス剤としてのスルファモイルベンズアミド誘導体
WO2013010069A1 (en) 2011-07-13 2013-01-17 Indiana University Research And Technology Corporation Modified viral structural protein with antiviral activity
EP2800742B1 (en) 2012-01-06 2016-04-06 Janssen Sciences Ireland UC 4,4-disubstituted-1,4-dihydropyrimidines and the use thereof as medicaments for the treatment of hepatitis b
EA026957B1 (ru) 2012-08-28 2017-06-30 Янссен Сайенсиз Айрлэнд Юси Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b
KR102271574B1 (ko) 2012-08-28 2021-07-01 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 설파모일-아릴아미드 및 b형 간염 치료제로서의 그 용도
CA2881322A1 (en) 2012-09-10 2014-03-13 F. Hoffmann-La Roche Ag 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
HK1215030A1 (zh) 2012-11-09 2016-08-12 Indiana University Research And Technology Corporation 用於hbv組裝效應劑的替代用途
WO2014089296A2 (en) 2012-12-06 2014-06-12 Institute For Hepatitis And Virus Research Functionalized benzamide derivatives as antiviral agents against hbv infection
BR112015015584A2 (pt) 2012-12-27 2017-12-12 Baruch S Blumberg Inst novos agentes antivirais contra infecção por hbv
RU2519546C1 (ru) 2013-01-16 2014-06-10 Общество С Ограниченной Ответственностью "Биоинтегратор" (Ооо "Биоинтегратор") КОНЪЮГАТЫ И МАЛЫЕ МОЛЕКУЛЫ, ВЗАИМОДЕЙСТВУЮЩИЕ С РЕЦЕПТОРОМ CD16а
WO2014131847A1 (en) 2013-02-28 2014-09-04 Janssen R&D Ireland Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
AR095426A1 (es) 2013-03-14 2015-10-14 Onyx Therapeutics Inc Inhibidores tripeptídicos de la epoxicetona proteasa
EP3943087A1 (en) 2013-03-15 2022-01-26 Celgene CAR LLC Heteroaryl compounds and uses thereof
MX353412B (es) 2013-04-03 2018-01-10 Janssen Sciences Ireland Uc Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
DK2997019T3 (en) 2013-05-17 2018-12-03 Janssen Sciences Ireland Uc SULFAMOYLTHIOPHENAMIDE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATING HEPATITIS B
TWI733288B (zh) 2013-05-17 2021-07-11 愛爾蘭商健生科學愛爾蘭無限公司 胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途
BR112015028873A2 (pt) 2013-05-17 2017-07-25 Hoffmann La Roche heteroaril-diidro-pirimidinas interligados na posição 6, para o tratamento e profilaxia de infecção pelo vírus da hepatite b
EA031077B1 (ru) 2013-06-19 2018-11-30 Серагон Фармасьютикалз, Инк. Модулятор рецептора эстрогена и его применения
US9550742B2 (en) 2013-07-29 2017-01-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 11-OXO-10,11-dihydrodibenzo[B,F][1,4]thiazepine S-oxide derivatives and their use as dopamine D2 receptor antagonists
ES2748029T3 (es) 2014-03-13 2020-03-12 Univ Indiana Res & Tech Corp Moduladores alostéricos de proteína núcleo de hepatitis B
PL3154949T3 (pl) 2014-06-10 2018-08-31 Basf Se PODSTAWIONE ZWIĄZKI [1,2,4]TRIAZOLOWE i IMIDAZOLOWE JAKO FUNGICYDY
TWI721016B (zh) 2015-09-15 2021-03-11 美商艾森伯利生物科學公司 B型肝炎核心蛋白質調節劑
US10811219B2 (en) 2018-08-07 2020-10-20 Applied Materials Israel Ltd. Method for evaluating a region of an object

Also Published As

Publication number Publication date
IL273132A (en) 2020-04-30
CA2942533C (en) 2020-12-08
AU2015229174A1 (en) 2016-09-22
ZA201606209B (en) 2019-04-24
CN106413402A (zh) 2017-02-15
CA2942533A1 (en) 2015-09-17
EP3116316A1 (en) 2017-01-18
HUE046567T2 (hu) 2020-03-30
KR20160135747A (ko) 2016-11-28
DOP2016000233A (es) 2016-12-30
IL247575A0 (en) 2016-11-30
DK3116316T3 (da) 2019-08-19
NZ723972A (en) 2021-08-27
IL282391A (en) 2021-06-30
CN110437153A (zh) 2019-11-12
US10947224B2 (en) 2021-03-16
US20170015658A1 (en) 2017-01-19
ES2748029T3 (es) 2020-03-12
PT3116316T (pt) 2019-09-30
PL3116316T3 (pl) 2020-03-31
US10183936B2 (en) 2019-01-22
AP2016009477A0 (en) 2016-09-30
CL2016002269A1 (es) 2017-08-18
HRP20191444T1 (hr) 2019-11-29
AU2019203754A1 (en) 2019-06-20
EP3116316B1 (en) 2019-07-10
EP3974426A1 (en) 2022-03-30
RS59430B1 (sr) 2019-11-29
SG10202001506UA (en) 2020-04-29
JP6602311B2 (ja) 2019-11-06
KR102363174B1 (ko) 2022-02-15
CN106413402B (zh) 2020-10-30
IL273132B (en) 2021-05-31
AU2015229174B2 (en) 2019-04-11
PH12016501762A1 (en) 2017-02-06
US20180273521A1 (en) 2018-09-27
MX363600B (es) 2019-03-28
SG11201607268UA (en) 2016-09-29
JP2019151650A (ja) 2019-09-12
EP3116316A4 (en) 2018-05-23
EP3607950A3 (en) 2020-03-18
JP2017518959A (ja) 2017-07-13
US20230019129A1 (en) 2023-01-19
MX2019003525A (es) 2019-07-08
WO2015138895A1 (en) 2015-09-17
IL247575B (en) 2020-05-31
MX2016011800A (es) 2017-04-27
EP3607950A2 (en) 2020-02-12
PH12016501762B1 (en) 2023-01-11

Similar Documents

Publication Publication Date Title
PH12018500572A1 (en) Hepatitis b core protein modulators
MX2019003525A (es) Moduladores alostericos de proteina nucleo de hepatitis b.
NZ730809A (en) Methods for treating filoviridae virus infections
PH12017550022A1 (en) Phosphoramidates for the treatment of hepatitis b virus
EA201691726A1 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
NZ631726A (en) Therapeutic compounds for the treatment of viral infections
EA026667B9 (ru) Фармацевтическая композиция для лечения вируса гепатита с
MX2017000312A (es) Derivados de isoindolina para usarse en el tratamiento de una infeccion viral.
EA201500942A1 (ru) ПРОТИВОВИРУСНЫЙ ИНДОЛО[2,3-b]ХИНОКСАЛИН
EA201890818A1 (ru) Режим комбинированной терапии для лечения hcv
PH12017500816A1 (en) Long acting pharmaceutical compositions for hepatitis c
PH12017500820A1 (en) Combination long acting compositions and methods for hepatitis c
EA201691835A1 (ru) Аллостерические модуляторы капсидного белка гепатита в
BR112016020895A2 (pt) moduladores alostéricos da proteína do núcleo da hepatite b
HK40005971A (en) Phosphoramidates for the treatment of hepatitis b virus